Jeffery Allen, MD
Neurology · Minneapolis, MNNPI 1982894010
Payments from drug & device makers
Across 869 payments — averaging $1752.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$527K
- Argenx US, Inc.$316K
- Takeda Pharmaceuticals U.S.A., Inc.$193K
- AstraZeneca$181K
- Sanofi US Services Inc.$93K
- Alnylam Pharmaceuticals Inc.$82K
- plus $132K from 13 others
Across 4 payments — averaging $1759.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Octapharma USA, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 224 | $526,614 |
| Argenx US, Inc. | 169 | $316,071 |
| Takeda Pharmaceuticals U.S.A., Inc. | 110 | $192,594 |
| AstraZeneca(2 entities) | 170 | $180,904 |
| Sanofi US Services Inc. | 11 | $92,972 |
| Alnylam Pharmaceuticals Inc. | 88 | $81,720 |
| Sanofi | 16 | $38,376 |
| Johnson & Johnson | 16 | $24,535 |
| Akcea Therapeutics, Inc. | 32 | $22,819 |
| EMD Serono Research & Development Institute, Inc. | 2 | $10,611 |
| Amgen | 5 | $9,014 |
| Octapharma USA, Inc. | 14 | $8,077 |
| Grifols USA, LLC | 2 | $7,000 |
| Grifols Shared Services North America, Inc. | 2 | $5,700 |
| Biocryst Pharmaceuticals, Inc. | 1 | $2,320 |
| Daiichi Sankyo Inc. | 1 | $1,063 |
| Vertex | 3 | $1,020 |
| Janssen Research & Development, LLC | 2 | $1,000 |
| Pfizer | 1 | $450 |
How this compares
$1,522,859 in reported general payments places this provider in the 95th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Minneapolis
- Christopher StreibMinneapolis$1.4M
- Adam CarpenterMinneapolis$413K
- Leonardo Brito de AlmeidaMinneapolis$331K
- Paul TuiteMinneapolis$127K
- Elizabeth NeilMinneapolis$116K
- Jerrold VitekMinneapolis$97K
- Lauren SchrockMinneapolis$95K
- Brittani ConwayMinneapolis$76K
- Kamaskshi LakshminarayanMinneapolis$64K
- Jonathan CalkwoodGolden Valley$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.